Literature DB >> 29288777

Epidemiology and spa-type diversity of meticillin-resistant Staphylococcus aureus in community and healthcare settings in Norway.

F Di Ruscio1, J V Bjørnholt2, K W Larssen3, T M Leegaard4, A E Moen5, B F de Blasio6.   

Abstract

BACKGROUND: There has been a marked increase in the incidence of meticillin-resistant Staphylococcus aureus (MRSA) during the past decade in Norway; a country with one of the lowest prevalence rates and an active 'search-and-destroy' policy applied to hospital settings. AIM: To characterize the trends of notification rates of community-associated (CA) and healthcare-associated (HA) MRSA in Norway, and explore the diversity and circulation of MRSA spa types within and outside healthcare settings.
METHODS: A registry-based study on notified MRSA infections and colonizations was conducted in Norway between 2006 and 2015. The diversity and abundance of CA- and HA-MRSA spa types were compared using novel ecological diversity measures (Hill numbers).
FINDINGS: During the study period, the monthly notification rate increased 6.9-fold and 1.8-fold among CA- and HA-MRSA, respectively; the increase was steeper among colonizations than infections. In both settings, the distribution of spa types was uneven, with a few dominant spa types and many singletons. The spa-type diversity of CA-MRSA was higher than HA-MRSA in terms of different types (685 vs 481), and increased during the study period. However, the diversity associated with the dominant spa types was similar and remained stable. A high overlap of spa types was estimated between the settings; spa-t002, t019 and t008 were the most common.
CONCLUSION: The present findings suggest a strong connection between CA- and HA-MRSA epidemiology in Norway. If the fast-growing trend of CA-MRSA continues in the years to come, it may challenge current guidelines and infection control of MRSA in healthcare environments.
Copyright © 2018 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Diversity measures; Hill numbers; Incidence rate; MRSA epidemiology; Time trends; spa typing

Mesh:

Year:  2017        PMID: 29288777     DOI: 10.1016/j.jhin.2017.12.019

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  5 in total

1.  Quantifying the transmission dynamics of MRSA in the community and healthcare settings in a low-prevalence country.

Authors:  Francesco Di Ruscio; Giorgio Guzzetta; Jørgen Vildershøj Bjørnholt; Truls Michael Leegaard; Aina Elisabeth Fossum Moen; Stefano Merler; Birgitte Freiesleben de Blasio
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-01       Impact factor: 11.205

2.  Changing epidemiology of methicillin-resistant Staphylococcus aureus in a low endemicity area-new challenges for MRSA control.

Authors:  Jenna Junnila; Tiina Hirvioja; Esa Rintala; Kari Auranen; Kaisu Rantakokko-Jalava; Jaakko Silvola; Laura Lindholm; Kirsi Gröndahl-Yli-Hannuksela; Harri Marttila; Jaana Vuopio
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-01-27       Impact factor: 3.267

3.  A Comparison of the Epidemiology, Clinical Features, and Treatment of Acute Osteomyelitis in Hospitalized Children in Latvia and Norway.

Authors:  Elise Evja Thingsaker; Urzula Nora Urbane; Jana Pavare
Journal:  Medicina (Kaunas)       Date:  2021-01-04       Impact factor: 2.430

4.  A Sporadic Four-Year Hospital Outbreak of a ST97-IVa MRSA With Half of the Patients First Identified in the Community.

Authors:  Ingrid M Rubin; Thomas A Hansen; Anne Mette Klingenberg; Andreas M Petersen; Peder Worning; Henrik Westh; Mette D Bartels
Journal:  Front Microbiol       Date:  2018-07-10       Impact factor: 5.640

5.  Postoperative treatment after partial nail ablation of ingrown toenails - does it matter what we recommend? A blinded randomised study.

Authors:  S V Bernardshaw; Liv Helene Dolva Sagedal; Kristin Møystad Michelet; Christina Brudvik
Journal:  Scand J Prim Health Care       Date:  2019-05-03       Impact factor: 2.581

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.